home / stock / lixt / lixt news

LIXT News and Press, Lixte Biotechnology Holdings Inc. From 11/22/21

Stock Information
Company Name: Lixte Biotechnology Holdings Inc.
Stock Symbol: LIXT
Market: OTC
Website: lixte.com
Menu
LIXT LIXT Quote LIXT Short LIXT News LIXT Articles LIXT Message Board
Get LIXT Alerts

News, Short Squeeze, Breakout and More Instantly...
LIXT - LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THAT ENROLLMENT HAS RESUMED IN NATIONAL CANCER INSTITUTE'S TRIAL TO DETERMINE ABILITY OF LIXTE COMPOUND LB-100 TO ENTER RECURRENT, MALIGNANT BRAIN TUMORS

PASADENA, CA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc . (Nasdaq: LIXT) announced that the National Cancer Institute (NCI) has resumed enrolling patients into their pharmacologic study of the ability of Lixte’s lead compound, LB-100, to enter the brain ...
LIXT - Lixte Biotechnology to Discuss its Collaboration with Leading European Cancer Centers at the Benzinga Global Small Cap Conference on October 28

Studies to use genome wide functional genetic techniques to identify effective drug combinations and new drug targets for its lead clinical compound, LB-100 PASADENA, CA, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc . (Nasdaq: L...

LIXT - Lixte Biotechnology Announces Collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrecht) to Identify the Most Promising Drug Combinations for its Lead Clinical Compound, LB-100, for Cancer Treatment

PASADENA, CA, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings , Inc. ( Nasdaq: LIXT ) announced entry into a collaboration with the Netherlands Cancer Institute , Amsterdam (NKI) , one of the world’s leading comprehensive cancer centers, and O...

LIXT - Lixte Biotechnology's LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine Addiction

A series of recent pre - clinical reports demonstrat e s LB-100’s effectiveness in various non - neoplastic diseases that may benefit from PP2A inhibition PASADENA, C...
LIXT - TRVN, PIXY and OBLG among pre market gainers

Score Media and Gaming (NASDAQ:SCR) +65% Penn National Gaming inks deal to acquire Score Media and Gaming Ensysce Biosciences (NASDAQ:ENSC) +38% announces notice of allowance from the U.S. Patent and trademark office for Patent entitled “compositions comprising enzyme-cl...

LIXT - Best Biotech Penny Stocks For Your Small-Caps Watchlist Right Now

3 Hot Biotech Penny Stocks to Know About in August Biotech penny stocks have remained some of the most popular penny stocks to watch throughout the past year and a half. The obvious reason behind this is the impact of the pandemic and the resulting attention on the biotech industry....

LIXT - Arcturus Therapeutics, Translate Bio leads healthcare gainers; Neuronetics, Bright Health among major losers

Gainers: Arcturus Therapeutics ARCT +35%, Translate Bio TBIO +29%, Flora Growth (NASDAQ:FLGC) +27%, Lixte Biotechnology (NASDAQ:LIXT) +27%, Outlook Therapeutics (NASDAQ:OTLK) +23%. Losers: Neuronetics STIM -39%, Bright Health BHG -19%,&#x...
LIXT - LIXTE BIOTECHNOLOGY'S LB-100 ELICITS ANTI- TUMOR ACTIVITY IN SMALL LUNG CANCER MODELS BY UNIQUE MECHANISMS IN AN IMPORTANT PRE-CLINICAL STUDY

A Pre-Clinical Study Reports that LB -100 Potentiates Standard Therapy f or Small Cell Lung Cancer Providing a Strong Rational e f or a Clinical Trial o f LB -100 i n Small Cell Lung Cancer Recently Initiated a t ...

LIXT - LIXTE BIOTECHNOLOGY COMMENTS ON REPORT THAT ITS PP2A INHIBITOR LB-100 COMBINED WITH ANOTHER INVESTIGATIONAL AGENT STIMULATES BONE GROWTH IN MODELS OF DWARFISM

Altadena, CA, July 22, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc . ( Nasdaq:LIXTE ) a clinical-stage drug discovery company developing pharmacologically active drugs for improving cancer treatments, commented on pre-clinical research demonstrating that inhibitio...

LIXT - Lixte Biotechnology Comments on Outside Research Citing LB-100's PP2A Inhibition as a Potential Therapeutic Strategy for Triple-Negative Breast Cancer

Altadena, CA, July 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc . ( Nasdaq: LIXT ) (“Lixte” or the “Company”) noted that Julio Pimentel, a fourth-year doctoral student in the Wayne State University School of Medicine’s Cancer ...
Previous 10 Next 10